Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

1.105 +0.075 (+7.28%)
Streaming Delayed Price Updated: 9:36 AM EDT, Jun 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeoVax Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
GeoVax to Showcase Advancements in Vaccines &amp; Immunotherapies at the 2025 BIO CEO &amp; Investor Conference
ATLANTA, GA - February 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced... 
Via TheNewswire.com
Exposures COVID-19
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative
Harnessing AI to Revolutionize Vaccine and Therapy Development 
Via TheNewswire.com
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Supply Chain
Exposures Supply Chain
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability
Addressing Critical U.S. Vulnerabilities in Vaccine Supply and National Preparedness 
Via TheNewswire.com
Topics Supply Chain
Exposures Supply Chain
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy 
Via TheNewswire.com
Exposures Product Safety
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Preview: Geovax Labs
Via Benzinga
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Process Expected to Increase Production Yield, Flexibility at Lower Cost 
Via TheNewswire.com
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024
Advancements Position GEO-CM04S1 as a Leading Vaccine Candidate Addressing Unmet Medical Needs, Especially Among Immunocompromised Patients 
Via TheNewswire.com
Exposures COVID-19
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025
Company to provide updates on progress toward the BARDA-funded Phase 2b trial of GEO-CM04S1, its next-generation COVID-19 vaccine as well as for Gedeptin® (solid tumor therapy) and GEO-MVA... 
Via TheNewswire.com
Exposures COVID-19
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025
ATLANTA, GA - January 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced... 
Via TheNewswire.com
3 Penny Stocks Ready to Break Out in 2025
Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products. 
Via MarketBeat
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday
Via Benzinga
David Dodd, CEO of GeoVax Labs Inc. (NASDAQ: GOVX), to Present at NobleCon20
Via Investor Brand Network
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar. 
Via Benzinga
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In August 2024 – Where Do Tesla, Nvidia, Apple, AMD Stock Rank?
A look at the top 20 most-searched tickers on Benzinga Pro for the month of August. 
Via Benzinga
GeoVax to Participate in Upcoming Investor Conferences in September
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
WHO Seeks $135M In Funding To Fight Mpox: Outbreak 'Can Be Controlled, And Can Be Stopped'
To fight the mpox outbreak in Africa, the World Health Organization calls for funding help for its six-month plan. 
Via Benzinga
Snowflake, GeoVax, Zoom, Target, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Wednesday, major U.S. indices were positive, with the Dow Jones Industrial Average rising 0.1% to 40,890.49. 
Via Benzinga
Topics Stocks
Exposures US Equities
GeoVax Labs Stock Surges Ahead Of The Close, Shares Remain Volatile: What's Happening?
GeoVax Labs shares popped ahead of the close on Wednesday and continue to bounce around in extended trading following a report suggesting Wayne County confirmed its first case of mpox since 2022. 
Via Benzinga
BioMedNewsBreaks — GeoVax Labs Inc. (NASDAQ: GOVX) Enters $8.5M Registered Direct Offering with Institutional Investor
Via Investor Brand Network
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.